Get access

Preliminary Validation of Self-assessment Tool to Measure Imatinib Adherence in Patients with Chronic Myeloid Leukemia


For questions or comments, contact Mikael Daouphars, Department of Pharmacy, Cancer Centre Henri Becquerel, 1 rue d'Amiens, 76000 Rouen, France; e-mail:


Study Objectives

To develop and validate a self-assessment adherence tool for imatinib in patients with chronic myeloid leukemia (CML), and to correlate the use of this tool with response to treatment and adverse effects.


Retrospective cohort study.


Regional cancer center in France.


Forty-six patients with chronic phase CML treated with imatinib for 6 months or longer as of July 1, 2009.

Measurements and main results

We developed a self-assessment questionnaire consisting of 10 questions to identify patients who were nonadherent to their cancer treatment. Each answer was worth 1 point, resulting in a possible maximum score of 10. The questionnaire was validated in patients receiving imatinib, using an objective adherence evaluation: a patient's score on the self-assessment questionnaire was correlated with prescription refills, expressed as a medication possession ratio. A score of less than 8 was associated with a positive predictive value of 0.83 to have a medication possession ratio below 90%. With use of this questionnaire, half of the patients receiving imatinib would be identified as being nonadherent (sensitivity 0.5). Few adherent patients would be falsely identified as nonadherent, as the questionnaire's specificity was 0.97.


This self-assessment questionnaire was validated for the first time in patients receiving imatinib for CML treatment. It provides a simple practical tool for health care professionals to assess patient adherence during their routine clinical practice and to propose targeted interventions for those identified as possibly nonadherent.

Get access to the full text of this article